Charles M. Rudin, MD, PhD
The field of small cell lung cancer (SCLC) is experiencing an outpouring of new data. Much of the excitement surrounds immunotherapy, particularly following recent findings with atezolizumab (Tecentriq).
, Rudin, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, reflected on the latest developments in SCLC.
OncLive: Could you share your thoughts on some of the recent immunotherapy data reported in SCLC?
: This is an exciting time for SCLC; a lot of new targets are emerging and a lot of new strategies are now being deployed in the clinic. One of the recent success stories was the initial trial bringing the PD-L1 inhibitor atezolizumab into first-line treatment for patients with SCLC. This was a trial randomizing patients between carboplatin and etoposide, which is a standard of care, versus the same standard of care plus atezolizumab. This was positive for both progression-fee survival and OS.
... to read the full story